Concept and Practice of Therapeutic Teams
Proceedings of the 11th European Symposium on Clinical Pharmacy, Brussels 1982
Herausgeber: De Clercq, H.; Bonal, Joaquin; Poston, J. W.
Concept and Practice of Therapeutic Teams
Proceedings of the 11th European Symposium on Clinical Pharmacy, Brussels 1982
Herausgeber: De Clercq, H.; Bonal, Joaquin; Poston, J. W.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This 1983 book reports the proceedings of the eleventh European symposium on clinical pharmacy which was held in Brussels in October 1982. The theme of the symposium was the concept of the therapeutic team and the relative contributions and responsibilities of pharmacists, nurses and physicians to the planning and implementation of drug treatment regimens. The first section of the volume provides an introduction to the concept of the therapeutic team and reflects the views several medical professionals. The later sections cover the practice of the therapeutic team in parenteral nutrition,…mehr
This 1983 book reports the proceedings of the eleventh European symposium on clinical pharmacy which was held in Brussels in October 1982. The theme of the symposium was the concept of the therapeutic team and the relative contributions and responsibilities of pharmacists, nurses and physicians to the planning and implementation of drug treatment regimens. The first section of the volume provides an introduction to the concept of the therapeutic team and reflects the views several medical professionals. The later sections cover the practice of the therapeutic team in parenteral nutrition, oncology, dermatology, epilepsy, internal medicine, nuclear medicine and drug selection. Not only did this book review achievements and experiences in clinical pharmacy, but it also looked towards the future of clinical pharmacy development in Europe. It will still be of significant interest to clinical pharmacy specialists today.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 266
- Erscheinungstermin: 11. Februar 2011
- Englisch
- Abmessung: 229mm x 152mm x 16mm
- Gewicht: 437g
- ISBN-13: 9780521279178
- ISBN-10: 0521279178
- Artikelnr.: 33611989
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Cambridge University Press
- Seitenzahl: 266
- Erscheinungstermin: 11. Februar 2011
- Englisch
- Abmessung: 229mm x 152mm x 16mm
- Gewicht: 437g
- ISBN-13: 9780521279178
- ISBN-10: 0521279178
- Artikelnr.: 33611989
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Preface; Part I. Introduction: 1. Introductory remarks; Part II. The
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid
Preface; Part I. Introduction: 1. Introductory remarks; Part II. The
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid
Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3.
The view of a pharmacist; 4. The view of a physician; 5. The view of a
nurse; 6. The view of the clinical pharmacologist; 7. The view of an
academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition:
8. Parenteral nutrition - the team approach in a general hospital; 9.
Long-term follow-up in total parenteral nutrition; 10. Total parenteral
nutrition of children at the State University Hospital of Copenhagen; 11.
Compatibility of two different fat emulsions with amino-acids, carbohydrate
and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and
parenteral nutrition: postoperative complications and P. N. I.
relationship. Preliminary study; Part IV. Oncology: 13. Central nervous
system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14.
The treatment protocols of acute lymphoblastic leukemia in children; 15.
Guidelines for the safe handling of minibags; 16. Centralization of
preparation of cytotoxic drugs in the central pharmacy: one year of
experience; 17. Progress in the management of high dose methotrexate; 18.
Parmacokinetics of cytosine arabinoside in leukemic patients with normal
and impaired hepatic functions, preliminary results; PartV. Dermatology:
19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy:
20. Team treatment of epilepsy; 21. Practices of the therapeutic team in
epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23.
The role of clinical pharmacist in the monitoring of antiepileptic therapy
in clinics with ambulant patients, our experience with 45 patients; Part
VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic
strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like
drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear
Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear
medicine therapeutic team: the role of the physician; 27. Practice of the
nuclear medicine therapeutic team: the role of the physicist; 28. Practice
of the nuclear medicine therapeutic team: the role of the radiotherapist;
Part IX. Drug Selection: 29. Collaboration in drug selection - preparing
the London Hospital Formulary 1982 - guide to the prescribing of medicines:
introduction; 30. A clinician's view on the team approach to drug
selection; 31. A pharmacists view on the team approach to drug selection;
32. Conclusion; 33. Restrictive formulary management with consequences for
the treatment of individual patients; 34. Changes in patterns of analgesic
use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical
pharmacy improvement and interrelation with therapeutci team; 36. Clinical
pharmacist participation in a clinical trial - treatment of congestive
heart failure; 37. Metronidazole plasma levels after I. V. and rectal
administration; 38. Individual factors influencing aminoglycoside serum
levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four
pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a
calculator program for individualized estimation of pheyoin kinetic
parameters by a least-squares technique; 42. On the importance of regular
Al determination in patients on regular hemodialysis (RHD); 43. Manufacture
of dialysis concentrate at the level of a hospital; 44. Hospital
preparation of injectable drugs by means of a multi-additive pump; 45. How
to detect physico-chemical incompatabilities in I. V. admixtures; 46.
Preparation of an enema containing metaminosalicylic acid